Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. NORDIC GROWTH MARKET
  5. Dextech Medical AB
  6. Summary
    DEX   SE0005881489

DEXTECH MEDICAL AB

(DEX)
 SummaryChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   End-of-day quote. End-of-day quote Nordic Growth Market
09/03/2021 09/06/2021 09/09/2021 09/10/2021 09/14/2021 Date
22.4 22.9 23.2 23 22.5 Last
180 90 1 754 332 Volume
+1.82% +2.23% +1.31% -0.86% -2.17% Change
Estimated financial data (e)
Sales 2020 0,60 M 0,07 M 0,07 M
Net income 2020 -7,71 M -0,89 M -0,89 M
Net cash position 2020 6,09 M 0,70 M 0,70 M
P/E ratio 2020 -96,2x
Yield 2020 -
Sales 2021 0,64 M 0,07 M 0,07 M
Net income 2021 -6,08 M -0,70 M -0,70 M
Net cash position 2021 3,46 M 0,40 M 0,40 M
P/E ratio 2021 -84,7x
Yield 2021 -
Capitalization 336 M 38,7 M 38,7 M
EV / Sales 2020 1 241x
EV / Sales 2021 805x
Nbr of Employees 1
Free-Float 99,0%
More Financials
Company
Dextech Medical AB is a Sweden-based research company specialized in urologic oncology. It is focused on prostate cancer, but also other cancers and non-malignant diseases. It develops drug canditates based on modified carbohydrate molecule combined with active substances. The Company has a patented technology platform, GuaDex, and three drug candidates with patents or patent applications. The portfolio includes:... 
More about the company
All news about DEXTECH MEDICAL AB
08/30DEXTECH MEDICAL : Year-end report July 1, 2020 - June 30, 2021
AQ
08/30Dextech Medical AB Reports Earnings Results of the Fourth Quarter and Year En..
CI
08/30Dextech Medical AB Reports Earnings Results for the Fourth Quarter Ended June..
CI
08/24DEXTECH MEDICAL : is planning a new clinical study on multiple myeloma
AQ
08/24DexTech Medical AB Plans New Clinical Study on Multiple Myeloma
CI
05/10DEXTECH MEDICAL : confirms very positive results from myeloma studies
AQ
05/10DexTech Medical AB Confirms Very Positive Results from Myeloma Studies
CI
04/20DEXTECH MEDICAL : Interim report July 1, 2020 - March 31, 2021
AQ
04/20Dextech Medical AB Reports Earnings Results of the Third Quarter and Nine Mon..
CI
02/02Dextech Medical AB Reports Earnings Results of the Second Quarter and Half Ye..
CI
02/01DexTech Medical AB Receives Positive Results Regarding Multiple Myeloma
CI
2020Dextech Medical AB Publ Reports Earnings Results for the First Quarter Ended ..
CI
2020Dextech Medical AB Reports Earnings Results for the Second Quarter and Six Mo..
CI
2020Dextech Medical AB Reports Earnings Results for the Third Quarter and Nine Mo..
CI
2020Dextech Medical AB Reports Earnings Results for the Second Quarter and First ..
CI
More news
News in other languages on DEXTECH MEDICAL AB

- No features available -

More news
Chart DEXTECH MEDICAL AB
Duration : Period :
Dextech Medical AB Technical Analysis Chart | DEX | SE0005881489 | MarketScreener
Income Statement Evolution
Managers and Directors
Anders Ragnarson Holmberg Chief Executive Officer, MD & Director
Gösta Lundgren Chief Financial Officer & IR Manager
Svante Wadman Chairman
Rolf Weste Eriksson Director
Sten Nilsson Director
Sector and Competitors
1st jan.Capi. (M$)
DEXTECH MEDICAL AB-55.00%39
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850